| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT06563999 | Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare… | Lung Cancer Stage III | Recruiting |
| NCT05491811 | Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53… | Non-Small Cell Lung Cancer | Active, Not Recruiting |
| NCT03420508 | Treating Patients With Melanoma and ALK Alterations With Ensartinib | Melanoma | Active, Not Recruiting |
| NCT03213652 | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors… | Advanced Malignant Solid Neoplasm | Active, Not Recruiting |
| NCT03155620 | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed… | Advanced Malignant Solid Neoplasm | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT07448116 | Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors. | Solid Advanced Tumor | Recruiting |
| Phase 1 | |||
| NCT04837716 | Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV… | Metastatic Lung Non-Small Cell Carcinoma | Active, Not Recruiting |